A compound composition of traditional Chinese medicine and its application in anti-prostate cancer

Abstract

A traditional Chinese medicine compound combination with the anti-prostate cancer effect and its application. The traditional Chinese medicine compound combination comprises the following traditional Chinese medicine raw materials by weight: 4 to 12 parts of bark of Ailanthus altissima, 12 to 30 parts of Hedyotis diffusa, 3 to 15 parts of Curcuma zedoaria, 15 to 30 parts of Salvia miltiorrhiza, 5 to 15 parts of Prunella vulgaris, and 4 to 12 parts of Glycyrrhiza uralensis. For the traditional Chinese medicine compound combination with the anti-prostate cancer effect, the materials are selected and combined according to the theory of traditional Chinese medicine and the pathogenesis of prostate cancer, and the proportions of the components are scientific and reasonable. Results of pharmacology experiments and clinical experiments show that the traditional Chinese medicine compound has a good anti-prostate cancer effect, and not only can significantly inhibit the proliferation and growth of prostate cancer, but also can inhibit the migration, invasion, and metastasis of prostate cancer, significantly improves the quality of life of a tumor-burdened mice, and improves immune indexes of the tumor-burdened mice. In addition, administration of the compound is convenient and simple, and the compound brings no obvious adverse reaction. The traditional Chinese medicine compound can be developed as a new-generation anti-prostate cancer drug, and is expected to become an effective prescription for the treatment of prostate cancer.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a traditional Chinese medicine compound composition and its application in preparing anti-prostate cancer. Background technique [0002] Prostate cancer (PCa), as the most common malignant tumor of the male reproductive system, is a disease that occurs in elderly men, and its incidence increases with age. The incidence of prostate cancer is unevenly distributed around the world. Every year, there are more than 900,000 new cases worldwide, of which more than 260,000 cases die due to the progression of prostate cancer. The incidence of prostate cancer in European and American countries is significantly higher than that in Asia and Africa. In the United States, prostate cancer accounts for the first incidence rate and the second death rate of male tumors in the United States. In my country, the incidence of prostate cancer has increased by 70% compared with the past, ranking fir...

AI Technical Summary

Problems solved by technology

The latest drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of CRPC include Abiraterone (Abiraterone) and MDV3100 (Enzalutamide). Antagonists, these two drugs target the androgen receptor signaling pathway, and have achieved significant curative effects in the treatment of castration-resistant prostate cancer, but after the above-mentioned endocrine therapy and drug therapy targeting the androgen receptor, the patient still remains Drug resistance will occur, the treatment effect is very limited, and the cost is expensive, and the patient's economic ability is poor

In addition, the side effects caused by radiotherapy and chemotherapy are also the bottleneck of clinical treatment.

Images